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Study objectives. To assess serum amyloid alpha (SAA) pleural ﬂuid levels in parapneumonic eﬀusion (PPE) and to investigate
SAA diagnostic performance in PPE diagnosis and outcome. Methods. We studied prospectively 57 consecutive patients with
PPE (empyema (EMP), complicated (CPE), and uncomplicated parapneumonic eﬀusion (UPE)). SAA, CRP, TNF-α,I L - 1 β,
and IL-6 levels were evaluated in serum and pleural ﬂuid at baseline. Patients were followed for 6-months to detect pleural
thickening/loculations. Results. Pleural SAA levels (mg/dL) median(IQR) were signiﬁcantly higher in CPE compared to UPE
(P<0.04); CRP levels were higher in EMP and CPE compared to UPE (P<0.01). There was no signiﬁcant diﬀerence between
IL-1β,I L - 6 ,T N F - α level in diﬀerent PPE forms. No signiﬁcant association between SAA levels and 6-month outcome was
found. At 6-months, patients with no evidence of loculations/thickening had signiﬁcantly higher pleural ﬂuid pH, glucose levels
(P = 0.0 3 ) ,l o w e rL D H( P = 0.005), IL-1β levels (P = 0.001) compared to patients who presented pleural loculations/thickening.
Conclusions. SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis. SAA
levelsdidnotdemonstrateconsiderablediagnosticperformanceinidentifyingpatientswhodeveloppleuralthickening/loculations
after a PPE.
1.Introduction
Parapneumonic eﬀusions (PPE) aﬀect 60.000 adults each
year in the USA and UK and are associated with a morbidity
of over 15% [1–4]. PPE may present in diﬀerent forms, rang-
ing from a self-resolving parapneumonic pleural eﬀusion to
complicated multiloculated and purulent eﬀusions that may
impair respiratory reserve. In this respect, diagnosis should
be prompt especially in cases that drainage or/and more in-
vasive type of management may be required.
Currently, management options for PPE are based on
clinical and laboratory ﬁndings. Previous studies reported
that pH, glucose, and lactate dehydrogenase (LDH) levels are
strong indicators for the course of a PPE [5]. Other inves-
tigations reported that pleural ﬂuid inﬂammatory cytokines
which reﬂect the inﬂammatory and ﬁbrotic processes in PPE
such as TNF-α,I L - 1 β, and IL-6 can add useful information
and may help in diﬀerentiating complicated parapneumonic
eﬀusions (CPEs) from uncomplicated parapneumonic eﬀu-
sions (UPEs) [6–8]. For example, the combined sensitivity of
TNF-α and LDH to diagnose a complicated PPE is over 90%
[9].Otherbiomarkerswhichareassociatedwithmechanisms
implicated in the pathogenesis of pleural eﬀusions—that is
natriuretic peptides, SAA—have been also suggested to aim
in the diagnosis of pleural eﬀusions [10]. However, data for
the role of these indices in PPE are sparse, and their potential
role in the diagnosis and outcome of PPE is not clear.
In the present prospective study, we aimed to investigate
prospectively the role of SAA in the diagnosis and prognosis
of complicated eﬀusions.2 Mediators of Inﬂammation
2.MaterialsandMethods
Patients were recruited by consecutive sampling from the
emergency departments at the University Hospital of Larisa
and “Sismanoglio” General Hospital of Attica between Jan-
uary 2007 and January 2008. Patients were included in the
study when they fulﬁlled the following criteria: (i) pleural
eﬀusion characterized as exudates according to criteria sug-
gested by Light [5], (ii) predominance of neutrophils cells
in the pleural ﬂuid, (iii) diagnosis of pneumonia based on
ATS criteria, (iv) no antibiotics for PPE prior to admission.
Patients treated with local ﬁbrinolytics were excluded from
the study. The study was approved by the Local Ethical Com-
mittee, and all patients gave their consent to participate in
the study.
Previously accepted criteria were used for the deﬁnition
of PPE as Empyema (EMP) or, complicated parapneumonic
eﬀusion (CPE) or, uncomplicated parapneumonic eﬀusion
(UPE) [5, 11, 12]. EMP included grossly purulent PPE
and nonpurulent PPE if microorganisms were detected by
Gram-stained smears or by pleural ﬂuid cultures [12]. CPE
included nonpurulent eﬀusions with pleural ﬂuid pH level
<7.2 or, pleural ﬂuid glucose <40mg/dL or, pleural ﬂuid
LDH level >1000U/L [11] or, when there were apparent
loculations on the chest X-ray or ultrasound examination of
thechest.EﬀusionsweregroupedasUPEifnoneoftheabove
properties were present [11].
At baseline, patients underwent clinical and radiologic
assessment and were followed for up to 6 months. Treatment
of all cases was based on previously accepted guidelines, [13]
and ﬁbrinolytics were not used. Patients underwent clinical
and radiological evaluation at 6 months and were classiﬁed
according to the presence of loculations/pleural thickening/
respiratory impairment or not.
2.1. Biochemistry and Cytology of the Fluid. Pleural ﬂuid
samples were obtained at baseline by thoracentesis before the
institution of any antibiotic treatment and were immediately
analyzed for pH (Instrumentation Laboratory, USA). Total
cell count, diﬀerential cell count, total protein, glucose, and
LDH were measured in pleural ﬂuid and serum. Pleural
ﬂuid samples were centrifuged at 1500g for 15 minutes, and
the supernatant from each sample was stored at −80◦Ct o
measure Il-1β, Il-6, TNF-α and SAA and CRP.
2.2. Cytokine, SAA, and CRP Assays. SAA and CRP were
measured in serum and pleural ﬂuid using nephelometry
(Behring Nephelometer Analyzer II) using the N High Sensi-
tivitykit(DadeBehring,Marburg,Germany).Il-1b,Il-6,and
TNF-αinsupernatantofthesamplesweremeasuredbyusing
an immunoenzymometric assay (Biosource Inc; Europe
S.A.). The reproducibility of these assays was conﬁrmed by
performing repeated measurements on successive days.
2.3. Chest Ultrasound and Radiographic Assessment. Patients
underwent chest X-ray and ultrasound of the chest using
a linear transducer (Aloka Echo Camera SSD—650CL)f o r
evaluation of (a) the distance between parietal and visceral
Table 1: Baseline characteristics of all 57 participants.
Age 67.5 (57.25–71.75)
SpO2 95 (92.5–95.5)
CURB score 1 (1-2)
Comorbidities- Carlson index, n 1 (0–2)
Presence of chronic respiratory disease, n 18
Loculations in ultrasound, n 24
Septal thickening in ultrasound (mm) 3 (2-3)
Pleural eﬀusion extended in
>half hemithorax, n 9
>1/3 16
<1/3 18
Continuous data are expressed as median (IQR), otherwise indicated.
pleura, (b) the presence of septa/loculations or not, and (c)
the degree of septal thickening (mm). PPE were classiﬁed as
anechoic when echo-free spaces were present between the
visceral and parietal pleura, as echogenic when an internal
sonographic pattern was present and ech-ogenic septated.
2.4. Statistical Analysis. Descriptive statistics were used to
summarize the baseline characteristics, and the results
were expressed as means (SE) or stated otherwise. Normal
distribution was assessed using the Kolmogorov-Smirnov Z
test. ANOVA (with Bonferoni’s test for comparison between
groups) was applied for the comparison of continuous var-
iables. Categorical variables were compared using the chi-
square test. To determine the prognostic value of various
parameters in predicting favourable or not outcome, receiver
operating characteristic (ROC) curves were constructed to
assign cutoﬀ values and their diagnostic utility. A P value of
less than 0.05 was considered as statistically signiﬁcant. The
statistical package SPSS 13.0 (Chicago, Ill, USA) was used for
the entire analysis.
3. Results
The study population comprised 57 patients (39 men and
18 women), with median age of 67.5 (57.25–71.75) years.
Baseline characteristics of participants are presented in
Table 1. Twenty-six patients had UPE, 17 patients CPE, and
14 patients had EMP. At six months, 8 (14%) patients died,
8 (14%) presented evident loculations, and 5(8.7%) pleural
thickening >1mm. Thirty-six out of 57 patients (61.4%) had
a favorable course on the basis of an uneventful clinical
course and absence of loculations or pleural thickening.
3.1. Pleural Fluid SAA, CRP, TNF-a, IL1β,I L 6 . Pleural ﬂuid
characteristics are presented in Table 2.T o t a lw h i t ec e l l
counts (cells/μL ×103) median (IQR) were signiﬁcantly low-
er in UPE [7300 (2340–10950) P<0.009] and CPE [2600
(850–5600), P<0.015] compared to EMP. SAA pleural ﬂuid
levels (mg/dL) were signiﬁcantly higher in CPE [12.35
(2.6–30.8)] compared to UPE [6.2 (2.4–15.07)], (ANOVA,
P<0.04). CRP levels (mg/dL) were signiﬁcantly higher inMediators of Inﬂammation 3
Table 2: Pleural ﬂuid characteristics in diﬀerent PPE types.
EMP (n = 14) CPE (n = 17) UPE (n = 26)
T o t a lc e l lc o u n t ,c e l l s / μL×103∗∗,##,∧ 32 (9–109.5) 2.6 (0.85–5.6) 7.3 (2.34–10.95)
Neutrophils, % 80 (68–90) 83 (62.75–90) 73 (40–83)
Albumin g/dL∗,## 2.2 (1,75–2.9) 2.55 (1.775–3.05) 3.28 (3.32–4,68)
Protein, g/dL 4.65 (3.06–4.97) 4.71 (4.167–5.54) 4.35 (2.972–5.13)
Glucose, mg/dL∗∗,## 6 (1.85–46) 23 (5.45–58.25) 102 (90.5–125.7)
LDH, U/L∗∗,## 6035 (3138–10085) 2113 (1350–3521) 446.5 (332–575)
ph∗∗,## 6.768 (6.07–7.13) 6.92 (6.77–7.10) 7.409 (7.3727.45)
SAA, mg/dL∗,∧ 3.2 (0.6–8.9) 12.35 (2.6–30.8) 6.2 (2.4–15.07)
CRP, mg/dL∗∗,## 10 (4.1–11.8) 12.2 (7.85–14.42) 4.3 (1.9–5.82)
TNF-α, pg/mL 37.77 (13.45–55) 34.06 (22.57–101.79) 16.746 (9.456–42.59)
IL-1β, pg/mL 11.74 (3.15–26.52) 2.02 (0.88–5.30) 0.7485 (0.175–9.39)
IL-6, pg/mL 50.622 (27.45–73.8) 95.36 (76.93–197.78) 323.75 (1.83–398.55)
Data are presented as median (IQR). ∗P<0.05 and ∗∗P<0.01 between CPE and UPE. #P<0.05 and ##P<0.01 between UPE and EMP. ∧P<0.05 and
∧∧P<0.0 1b e t w e e nC P Ea n dE M P .E M P :E m p y e m a ,C P E :C o m p l i c a t e dP a r a p n e u m o n i cE ﬀusions, UPE: Uncomplicated Parapneumonic Eﬀusions.
Empyema [10 (4.1–11.8)] and CPE [12.2 (7.85–14.42)]
compared to UPE [4.3 (1.9–5.82)] (P<0.01). There were no
statistically signiﬁcant diﬀerences in terms of TNF-α,I L - 1 β,
and IL-6 between groups.
3.2. Serum SAA, CRP, TNF-α,I L 1 β,I L 6 .Serum levels of
biochemical parameters and of diﬀerent cytokines are shown
in Table 3. Median (IQR) SAA serum levels were found
higher in CPE [80.95 (31.73–98.575)] compared to UPE
[29.25 (7.525–74.225) (P = 0.079)] and EMP [52.2 (28.7–
62.4) (P = 0.579)], but there was no statistical signiﬁcance.
CRPwassigniﬁcantlyhigherinCPE[18.75(15.4–20.4)]than
UPE [7.25 (4–16.85), P<0.011]. There were no diﬀerences
in terms of TNF-α,I L - 1 β, and IL-6 between groups.
3.3. Relationship between Inﬂammatory Markers and PPE
Outcome at 6 Months. Patients with favorable outcome (un-
eventful clinical course, absence of loculations or pleural
thickening) had signiﬁcantly higher pleural ﬂuid pH and
glucose levels (P = 0.03 and P = 0.03, resp.) and lower LDH
levels (P = 0.005) compared to patients who presented locu-
lations/pleural thickening at 6 months (Table 4). In addition,
IL-1β was signiﬁcantly higher in the pleural ﬂuid of patients
with loculations/pleural thickening [13.33 (10.15–30.44)]
compared to patients with favorable outcome [2.01 (0.80–
11.89) (P<0.05)]. No signiﬁcant diﬀerences were found in
terms of SAA, CRP, TNF-α, IL-6 levels in pleural ﬂuid.
ROC analysis evaluated the diagnostic performance
of inﬂammatory pleural ﬂuid markers in the diagnosis
of outcome at 6 months. AUC for ph, glucose, LDH were
0.65, 0.73, and 0.72, respectively (Figure 1). A cutoﬀ point
of >120mg/dL pleural glucose had 100% speciﬁcity for the
diagnosis of favourable outcome; accordingly, the cut-oﬀ
point for LDH was <160mg/dL.
4. Discussion
In the present study we found that SAA levels in pleural ﬂuid
were signiﬁcantly higher in patients with CPE compared
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Figure 1: ROC curves for SAA, Glucose, pH, LDH in identifying
PPE patients with favourable course and outcome at 6 months.
to UPE. This ﬁnding suggests that SAA might play a role
in the inﬂammatory process that characterizes parapneu-
monic eﬀusions. However, our ﬁndings did not support the
hypothesis that SAA might have also a role in the prediction
of clinical course of PPE. Despite that several biochemical
markers of inﬂammation such as pleural pH, glucose,
LDH, and CRP were signiﬁcantly associated with 6-month
outcome, SAA did not present signiﬁcant diagnostic per-
formance in identifying patients who would present pleural
thickening/loculations or die at 6 months following admis-
sion for PPE.
TheroleofSAAinPPEisnotwellknown.Onlyonestudy
conducted by Okino et al. [10] investigated the role of SAA
in patients with PPE. The authors compared pleural SAA,
CRP, and pleural ﬂuid/serum ratios and pointed out SAA
as a very good marker in discriminating between exudates4 Mediators of Inﬂammation
Table 3: Serum levels of biochemical parameters and of diﬀerent cytokines in PPE.
EMP (n = 14) CPE (n = 17) UPE (n = 26)
Glucose, mg/dL 124 (102–182.5) 97 (86–141) 101 (88–120)
LDH, U/L 288 (202–325) 266 (259–301) 264.5 (234.25–286.75)
pH 7.465 (7.443–7.5) 7.47 (7.445–7.485) 7.47 (7.445–7.488)
SAA, mg/dL 52.2 (28.7.–62.4) 80.95 (31.73–98.575) 29.25 (7.525–74.225)
CRP, mg/dL∗ 11.9 (10–19) 18.75 (15.4–20.4) 7.25 (4–16.85)
TNF-α pg/mL 10.24 (7.783–12.55) 14.96 (8.1–19.44) 13.42 (5.86–18.29)
IL-1β pg/mL 0.9 (0.79–1.065) 0.66 (0.4475–1.66) 1.365 (0.6725–13.39)
IL-6 pg/mL 44.69 (26.17–56.99) 56.52 (36.75–83.44) 64 (16.35–101.11)
Data are presented as median (IQR). ∗P<0.0 1b e t w e e nC P Ea n dU P E .E M P :E m p y e m a ,C P E :C o m p l i c a t e dP a r a p n e u m o n i cE ﬀusions, UPE: Uncomplicated
Parapneumonic Eﬀusions.
Table 4: Pleural ﬂuid characteristics in PPE according to outcome at 6 months.
Favourable outcome (n = 36) Loculation/pleural thickening (n = 13) Died (n = 8)
T o t a lc e l lc o u n t ,c e l l s / μL ×103 7.2 (4.2–12) 4.37 (9.06–182.5) 2 (1.09–13.84)
Protein, g/dL 4.6 (3.75–5.27) 4.35 (2.945–4.8225) 4.3 (2.69–4.8)
Glucose, mg/dL∗ 89 (56.45–112.75) 5.5 (1.52–67) 60 (13.5–83.5)
LDH, U/L+∗∗ 603 (340.25–1655) 6641 (2334–9828) 625 (463.5–9646)
pH∗∗ 7.34 (6.95–7.43) 6.81 (6.21–7.06) 7.35 (7.03–7.41)
SAA, mg/dL 6.7 (2.55–13.3) 7.05 (1.27–16.87) 1.05 (0.4–4.62)
CRP, mg/dL 5.2 (2.5–11.55) 7.4 (4.07–11.72) 4.6 (2.72–7.59)
TNF-α, pg/mL 25.17 (11.77–59.73) 41.15 (6.67–57.69) 22.95 (12.31–43.45)
IL-1β,p g / m L ∗ 2.01 (0.80–11.89) 13.33 (10.15–30.44) 0.56 (0.162–25.54)
IL-6, pg/mL 341.83 (146.56–383.47) 2.456 4.279 (2.6415–239.111)
Data are presented as median (IQR).
∗P<0.05 and ∗∗P<0.01 between favorable outcome and loculations.
and transudates. In agreement with that study [10], SAA
pleural ﬂuid levels (mg/dL) in the present investigation were
signiﬁcantly higher in CPE compared to UPE (P<0.04).
However in the present study we followed patients for 6
months, and we provided further data regarding the rela-
tionship between SAA and the clinical, radiologic outcome
of patients with PPE. SAA failed to show a signiﬁcant as-
sociation with the outcome of PPE. In contrast, parameters
which have been previously related to prognosis and have
been widely used for management decisions [5]p r e s e n t e d
remarkable diagnostic performance. Notably, the diagnostic
performances of pleural glucose and LDH in identifying
patients with favourable outcome at 6 months were con-
siderable; pleural glucose value of >120mg/dL or LDH
of <160mg/dL had 100% speciﬁcity for the diagnosis of
favourable outcome. In this respect, our results suggest that
SAA could be used at least, as an alternative marker for dis-
criminating between CPE and UPE.
SAA is a protein which is usually produced in the acute
phaseofinﬂammation-asCRP-andinthisrespecttheﬁnding
of elevated levels in PPE might not be surprising [14–16].
However, SAA levels were signiﬁcantly higher in patients
with complicated eﬀusions. In this respect, increased SAA
levels might represent the burden of inﬂammation in the
pleura. On the other hand, SAA levels in EMP were low—
notable are the levels that were similar to uncomplicated
eﬀusions. A plausible explanation for this might be the fact
that SAA is a protein that can be easily degraded in the puru-
lent environment of EMP where neutrophils predominate
[17].
SAA predominantly produced and secreted mainly by
hepatocytesandbyothercellsincludinglymphocytes,mono-
cytes, and macrophages [14, 15]. Induction of SAA synthesis
is triggered by a number of cytokines, chieﬂy IL-6, which is
released from a variety of cell types, but mainly from ma-
crophages and monocytes at inﬂammatory sites [16]. TNF-
α and IL-1β may also act as inﬂammatory mediators that
induce SAA [18]. In the present study, we therefore, mea-
sured levels of these cytokines in the pleura ﬂuid and serum.
We found no signiﬁcant correlation between SAA levels and
TNF-a, IL-6, or IL-1β.H o w e v e r ,t h i sd o e sn o te x c l u d ea n y
relationship between SAA and TNF-a, IL-6 or IL-1β because
these cytokines are widely involved in the inﬂammatory
cascade, might be aﬀe c t e db ym a n yf a c t o r sa n dc o u l db e
upregulated in PPE regardless of SAA levels. TNF-a, IL-6,
or IL-1β regulate the growth and diﬀerentiation of a variety
of immune cells and play role in a variety of inﬂammatory
reactions. Notably, IL-6 is often used as a marker of systemic
activation of proinﬂammatory cytokines [19]. Increased
levels of TNF-α have been found in various infections
and in parapneumonic eﬀusions [9, 20]. IL-1β has various
biologic activities, principally as an immunomodulator and
proinﬂammatory mediator per se or via induction of other
cytokines and inﬂammatory mediators [21].Mediators of Inﬂammation 5
On this basis the levels of these cytokines vary in dif-
ferent studies where diﬀerent populations were included and
diﬀerent techniques were used. Thus, Silva-Mejias et al.
showed that IL-1β levels were >200pg/mL in patients with
parapneumonic eﬀusions [22], but in another study [23]
levels in infectious and neoplastic etiologies were similar. In
our study, there was a trend towards higher IL-1β levels in
CPE compared to UPE (P<0.088). In this respect, univer-
sally accepted cut-oﬀ diagnostic values in the case of PPE are
hard to be applied. However, these cytokines may reﬂect the
burden of the systemic inﬂammation or the inﬂammatory
process in the pleura and might provide useful information.
Notably, in our study, IL-1β was associated with the outcome
at 6-month.
In conclusion, our ﬁndings suggest that SAA is increased
in complicated PPE, and it might be used as an alternative
biomarker in the diagnosis of nonpurulent complicated par-
apneumonic eﬀusions. However, SAA levels did not demon-
strate considerable performance in identifying patients who
develop pleural thickening or loculations after a PPE in our
study, whereas classic parameters such as pH, glucose, and
LDH did. In this respect, based on the current clinical man-
agement of PPE [24], the present study cannot advocate the
use of SAA in the routine practice.
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